The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study.
 
Lisa Derosa
No Relationships to Disclose
 
Bertrand Routy
No Relationships to Disclose
 
Laurence Zitvogel
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Pfizer (Inst)
Research Funding - H-2020; Torino Lumiere
 
Andrew M. Thomas
No Relationships to Disclose
 
Gerard Zalcman
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Inventiva Pharma; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Inventiva Pharma (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche (Inst); ROCHE (Inst); ROCHE (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer; Pfizer; Roche
 
Sylvie Friard
No Relationships to Disclose
 
Julien Mazieres
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Hengrui Therapeutics; Lilly/ImClone; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Clarisse Audigier-Valette
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche; Sysmex
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Msd (Inst); Novartis (Inst); Pfizer (Inst); Roche; Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
 
Denis Moro-Sibilot
Consulting or Advisory Role - Abbvie; Amgen; ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly/ImClone; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim France (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Expert Testimony - MSD Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly/ImClone; MSD Oncology; Pfizer; Roche/Genentech
 
Francois Goldwasser
No Relationships to Disclose
 
Corentin Richard
No Relationships to Disclose
 
François Ghiringhelli
No Relationships to Disclose
 
Fabrice Barlesi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Seagen; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
 
Arielle Elkrief
No Relationships to Disclose
 
Carolina Alves Costa Silva
No Relationships to Disclose
 
David Planchard
No Relationships to Disclose
 
Nicola Segata
Stock and Other Ownership Interests - PreBiomics
Honoraria - Zoe Global Ltd.
Consulting or Advisory Role - YSOPIA Bioscience; Zoe Global Ltd.
Patents, Royalties, Other Intellectual Property - Patents pending with PreBiomics
 
Stéphanie Martinez
No Relationships to Disclose
 
Jean-Charles Soria
Employment - AstraZeneca/MedImmune
Leadership - Hookipa Pharma
Stock and Other Ownership Interests - AstraZeneca; Daiichi Sankyo (I); Gritstone Bio
Honoraria - Relay Therapeutics
 
Benjamin Besse
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cergentis (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Janssen Oncology (Inst); Lilly (Inst); Onxeo (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst)